Brimarafenib

Brimarafenib
Clinical data
Other names	BGB-3245
Identifiers
	IUPAC name 1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2,4,5-trifluorophenyl)urea;
CAS Number	1643326-82-2;
PubChem CID	117807031;
IUPHAR/BPS	13203;
ChemSpider	129144353;
UNII	GXS33OY2CB;
Chemical and physical data
Formula	C24H17F3N4O4
Molar mass	482.419 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(=O)NC2=NC=CC(=C21)OC3=CC4=C(C=C3)O[C@H]5[C@@H]4[C@@H]5NC(=O)NC6=CC(=C(C=C6F)F)F;
	InChI InChI=InChI=1S/C24H17F3N4O4/c25-13-8-15(27)16(9-14(13)26)29-24(33)31-21-20-12-7-10(1-3-17(12)35-22(20)21)34-18-5-6-28-23-11(18)2-4-19(32)30-23/h1,3,5-9,20-22H,2,4H2,(H,28,30,32)(H2,29,31,33)/t20-,21-,22-/m0/s1; Key:USMWOBMHNWNPAP-FKBYEOEOSA-N;

Brimarafenib is an investigational new drug that is being evaluated for the treatment of cancer. It targets the proto-oncogene BRAF with activating mutations BRAF mutations (such as V600E), non-V600 BRAF mutations, and RAF fusions.^[1]^[2]

It is being developed by MapKure, LLC, a joint venture between SpringWorks Therapeutics and BeiGene.^[1]

References

1 2 "Brimarafenib".
↑ Tellenbach FL, Seiler LL, Johnson M, Rehrauer H, Schukla P, Martinez-Gomez J, et al. "Combination of the Novel Raf Dimer Inhibitor Brimarafenib with the Mek Inhibitor Mirdametinib is Effective Against Nras Mutant Melanoma". SSRN 4934723. doi:10.2139/ssrn.4934723.

[patsnap-1] 1 2 "Brimarafenib".

[2] Tellenbach FL, Seiler LL, Johnson M, Rehrauer H, Schukla P, Martinez-Gomez J, et al. "Combination of the Novel Raf Dimer Inhibitor Brimarafenib with the Mek Inhibitor Mirdametinib is Effective Against Nras Mutant Melanoma". SSRN 4934723. doi:10.2139/ssrn.4934723.

[1]

[2]